30 Years, 1000+ Cases

Since 1995, Equinox Group has provided analytics to support R&D decisions at biopharmaceutical firms, assessing the potential of drugs from discovery to launch, and anywhere in between. Our validated techniques will save you time and money, as well as overcome the deficiencies of traditional market research.

We have evaluated the potential of thousands of drug profiles across hundreds of indications in oncology, immunology, rare diseases, cardio-metabolic disorders, infectious diseases, neurology, respiratory, urology, ophthalmology, and endocrine disorders. We also have tailored methods to solve the unique analytical challenges that arise in oncology and rare diseases.

Equinox Group specializes in predicting the commercial performance of drug programs in all stages of research and development, delivering quantitative insights regarding: disease area strategy, market access, patient share, patient flow, and epidemiology